Skip to main content
Log in

Pharmacokinetics of endralazine

  • Letters To The Editors
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Meredith PA, Elliott HL, McSharry D, Kelman AW, Reid JL (1983) The pharmacokinetics of endralazine in essential hypertensives and in normotensive subjects. Br J Clin Pharmacol 16: 27–32

    Google Scholar 

  2. Reece PA, Cozamanis I, Zacest R (1983) Endralazine — a new hydralazine-like antihypertensive with high systemic bioavailability. Eur J Clin Pharmacol 25: 553–556

    Google Scholar 

  3. Reece PA, Cozamanis I, Zacest R (1982) Influence of acetylator phenotype on the pharmacokinetics of a new vasodilator anti-hypertensive endralazine. Eur J Clin Pharmacol 23: 523–527

    Google Scholar 

  4. Boxenbaum HG, Riegelman S, Elashoff RM (1974) Statistical estimations in pharmacokinetics. J Pharmacokinet Biopharm 2 [2]: 123–148

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Elliott, H.L., Meredith, P.A. & Reid, J.L. Pharmacokinetics of endralazine. Eur J Clin Pharmacol 26, 661 (1984). https://doi.org/10.1007/BF00543509

Download citation

  • Received:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00543509

Key words

Navigation